Renal nerve ablation after SYMPLICITY HTN-3: Confused at the higher level?

European Heart Journal

Volumn 35, Issue 26, 2014, Pages 1706-1711

  Lüscher, Thomas F ^a,b   Mahfoud, Felix ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; EPLERENONE; GUANETHIDINE; RENIN INHIBITOR; RESERPINE; SPIRONOLACTONE;

ADRENERGIC SYSTEM; HEART CATHETER; HEART CATHETERIZATION; HUMAN; KIDNEY DENERVATION; KIDNEY NERVE; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RESISTANT HYPERTENSION; REVIEW; SYMPATHETIC NERVE; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE; WHITE COAT HYPERTENSION; BLOOD PRESSURE; CATHETER ABLATION; DRUG RESISTANCE; HYPERTENSION; INNERVATION; KIDNEY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPATHECTOMY;

BLOOD PRESSURE; CATHETER ABLATION; DRUG RESISTANCE; HUMANS; HYPERTENSION; KIDNEY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT FAILURE;

EID: 84906510065     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu195     Document Type: Review

References (26)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe: epidemiological update. Eur Heart J 2013;34:3028-3034.
2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. 2013 ESH/ ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2014;23:3-16.
3. Burnier M, Vuignier Y, Wuerzner G. State-of-the-art treatment of hypertension: established and new drugs. Eur Heart J 2014;35:557-562.
4. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC Jr, Crowley K, Goto S, Ohman EM, Bakris GL, Perlstein TS, Kinlay S, Bhatt DL; REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J 2013;34:1204-1214.
5. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012;125:1594-1596.
6. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-1642.
7. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, ToennesSW. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013;31:766-774.
8. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013;128: 132-140.
9. Brguljan-Hitij J, Thijs L, Li Y, Hansen TW, Boggia J, Liu YP, Asayama K, Wei FF, Bjorklund-Bodegard K, Gu YM, Ohkubo T, Jeppesen J, Torp-Pedersen C, Dolan E, Kuznetsova T, Katarzyna SS, Tikhonoff V, Malyutina S, Casiglia E, Nikitin Y, Lind L, Sandoya E, Kawecka-Jaszcz K, Filipovsky J, Imai Y, Wang J, O'Brien E, Staessen JA; on behalf of the International Database on Ambulatory blood pressure in relation to Cardiovascular Outcome Investigators. Risk stratification by ambulatory blood pressure monitoring across JNC classes of conventional blood pressure. Am J Hypertens 2014;in press.
10. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603.
11. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, Esler MD, Schlaich MP. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013;61:457-464.
12. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-1909.
13. Mahfoud F, Luscher TF, Andersson B, Baumgartner I, Cifkova R, Dimario C, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefèvre T, Lotan C, Sievert H, Volpe M, Widimsky P, WijnsW, Williams B, Windecker S, Witkowski A, Zeller T, Böhm M; European Society of Cardiology. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013;34:2149-2157.
14. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C; European Society of Hypertension. Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention 2013;9 Suppl R:R58-R66.
15. Kandzari DE, Bhatt DL, Sobotka PA, O'NeillWW, Esler M, Flack JM, Doevendans P, Fagard R, Fajadet J, Komajda M, Lefèvre T, Lotan C, Sievert H, Volpe M, Widimsky P, Wijns W, Williams B, Windecker S, Witkowski A, Zeller T, Böhm M; European Society of Cardiology. Catheter-based renal denervation for resistant hypertension: rationale and design of theSYMPLICITY HTN-3 Trial. Clin Cardiol 2012;35:528-535.
16. Bhatt DL, Kandzari DE, O'NeillWW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators.Acontrolled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-1401.
17. Mahfoud F, Bhatt DL. Catheter-based renal denervation: the black box procedure. JACC Cardiovasc Interv 2013;6:1092-1094.
18. Laurent S, Schlaich M, Esler M. Newdrugs, procedures, and devices for hypertension. Lancet 2012;380:591-600.
19. Rifkin DE, Khaki AR, Jenny NS, McClelland RL, Budoff M,Watson K, Ix JH, Allison MA. Association of renin and aldosterone with ethnicity and blood pressure: the multiethnic study of atherosclerosis. Am J Hypertens 2014;in press.
20. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
21. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, CaspersonP,Harris CL,ChaitmanBR, ShawL,Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-1516.
22. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
23. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
24. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011;123:1940-1946.
25. Lüscher TF, Wolfrum M, Noll G, Sudano I. Renal sympathetic denervation. In: Eckhout E. SPW, Wijns W, Vahanian A, van Sambeek M, de Palma R. eds. The PCR-EAPCI Textbook. Paris: Europa Edition; 2012.
26. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383: 622-629.